Lipocine receives FDA clearance for clinical testing its NASH candidate, LPCN 1144
Lipocine announced it has received clearance from the FDA to clinically investigate LPCN 1144 in an expanded target population of adult male non-alcoholic steatohepatitis patients. The FDA has waived the limitation of only testing in NASH subjects with total testosterone levels below 300 ng/dL. July 23, 2019